Wednesday, 14 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)
Hye Jung Park, MD
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Yoon Hee Park
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Heejae Han
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Junho Kim, MD
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Kyung Hee Park, MD
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Jung-Won Park, MD, PhD
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Jae-Hyun Lee, MD, PhD
,
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background: CD93 is receiving renewed attention as a biomarker of inflammation in various inflammatory and immune-mediated diseases. Asthma is a chronic inflammatory airway disease; very few serologic biomarkers of inflammation have been reported to date. Moreover, to our knowledge, the clinical meaning of serum soluble CD93 (sCD93) in asthmatics has not been studied. We aimed to evaluate the potential of serum sCD93 as a novel biomarker of allergic inflammation in asthmatics.
Methods: Serum sCD93 levels of 116 asthmatic patients were determined and correlated with comorbidity, medical condition, medication history, lung function, and serologic and sputum markers.
Results: The mean serum sCD93 level was 115.4 ± 34.8 ng/mL (range, 36.3–241.0 ng/mL). Serum neutrophil level (standardized coefficient −0.232, P = 0.027) and forced expiratory volume in one second/forced vital capacity (FEV1/FVC; standardized coefficient −0.322, P = 0.015) were negatively correlated with sCD93 levels. sCD93 levels showed no significant correlation with serum eosinophil, sputum eosinophil, sputum neutrophil levels, and FEV1. sCD93 levels were significantly lower in high-dose inhaled corticosteroid (ICS) users (84.1 ± 28.9 ng/mL) than those in ICS non-users (128.9 ± 35.8 ng/mL) and low-medium-dose ICS users (114.5 ± 33.2 ng/mL). The high-sCD93 group had significantly heavier smoking history than the other groups.
Conclusions: The serum sCD93 levels are associated with neutrophilic inflammation and ICS dose in asthmatic patients. We suggest that sCD93 has potential as a novel biomarker that reflects the level of inflammation and as a follow-up marker during ICS use.
